NG2 has been the subject of much recent investigation and has become a novel therapeutic target for KMT2A-r ALL due to its predictive value, because it contributes to leukemia invasiveness and CNS infiltration, and more frequent CNS relapse [13,14,15]. This evidence concerns the gene CSPG4 and leukemia.